Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

European Journal of Nuclear Medicine

Volumn 26, Issue 3, 1999, Pages 226-230

  Boerner, A R ^a   Weckesser, M ^b   Herzog, H ^b   Schmitz, T ^b   Audretsch, W ^b   Nitz, U ^b   Bender, H G ^b   Mueller Gaertner, H W ^b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b NONE

Author keywords

Breast cancer; Contrast parameters; Fluorine 18 fluorodeoxyglucose; Positron emission tomography; Tumour to non tumour ratio

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE;

ADULT; ARTICLE; BODY POSTURE; BREAST BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HUMAN; IMAGE ANALYSIS; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

DISEASES; ELECTRONS; IMAGE ENHANCEMENT; MEDICAL IMAGING; POSITRONS; TUMORS;

BREAST CANCER; CONTRAST PARAMETER; FLUORINE-18; FLUORINE-18 FLUORODEOXYGLUCOSE; FLUORINE-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHIES; FLUORODEOXYGLUCOSE; IMAGING PROTOCOL; SCAN TIME; STANDARDIZED UPTAKE VALUES; TUMOR-TO-NONTUMOR RATIO;

POSITRON EMISSION TOMOGRAPHY;

EID: 0032991126     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050381     Document Type: Article

References (32)

1. 1. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fiuoro-D-glucose PET. Radiology 1993; 187: 743-50.
2. 2. Avril N, Dose J, Janicke F, Ziegler S, Römer W, Weber W, Herz M, Nathrath W, Graeff H, Schwaiger M. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88: 1204-1209.
3. 3. Avril N, Dose J, Janicke F, Bense S, Ziegler S, Laubenbacher C, Römer W, Pache H, Herz M, Allgayer B, Nathrath W, Graeff H, Schwaiger M. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14: 1848-1857.
4. 4. Crowe JPJ, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994; 1: 132-140.
5. 5. Hawkins RA, Hoh C, Glaspy J, Rege S, Choi Y, Phelps ME. Positron emission tomography scanning in cancer. Cancer Invest 1994; 12:74-87.
6. 6. Wahl RL, Cody R, Hutchins G, Mudgett E. Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose. NEnglJMed 1991; 324: 200.
7. 7. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72:2979-2985.
8. 8. Reske SN, Bares R, Büll U, Guhlmann A, Moser E, Wannenmacher MF. Clinical value of positron emission tomography (PET) in oncology: results of an interdisciplinary consensus conference. Nuklearmedizin 1996; 35:42-52. Update: Moser E, Krause T. Konsensus Onko-PET. Nuklearmedizin 1997; 36: 45-46.
9. 8. Reske SN, Bares R, Büll U, Guhlmann A, Moser E, Wannenmacher MF. Clinical value of positron emission tomography (PET) in oncology: results of an interdisciplinary consensus conference. Nuklearmedizin 1996; 35:42-52. Update: Moser E, Krause T. Konsensus Onko-PET. Nuklearmedizin 1997; 36: 45-46.
10. 9. Nitzsche EU, Hoh CK, Dalbohm NM, Glaspy JA, Phelps ME, Moser EA, Hawkins RA. Whole body positron emission tomography in breast cancer. Röfo 1993; 158: 293-298.
11. 10. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23: 1588-1593.
12. 11. Price P, Jones T. Can positron emission tomography be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 12: 1924-1927.
13. 18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15: 61-66.
14. 13. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
15. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995; 21: 280-283.
16. 11C]tyrosine PET. J Nucl Med 1997; 5: 692-696.
17. 18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung. Eur J Nucl Med 1996; 23: 517-523.
18. 17. Schomburg A, Bender H, Reichelt C, Sommer T, Ruhlmann J, Kozak B, Biersack HJ. Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures. Eur J Nucl Med 1996; 23:571-574.
19. 18. Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
20. 19. Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, Romer W, Janicke F, Schwaiger M. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997; 38: 1186-1191.
21. 20. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998; 207: 767-774.
22. 21. Palmedo H, Bender H, Grünwald F, Mallmann P, Zamora P, Krebs D, Biersack HJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium99 m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997; 24: 1138-1145.
23. 22. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-Fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
24. 23. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
25. 24. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 11: 1771-1776.
26. 25. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25: 259-264.
27. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25: 1255-1260.
28. 27. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med 1997; 24: 691-705.
29. 28. Fischman AJ, Alpert MN. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 1993; 34: 1-6.
30. 29. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35: 1308-1312.
31. 18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: preliminary observation. Eur J Nucl Med 1998; 25: 1429-1434.
32. 31. Hawkins RA, Choi Y, Huang SC, Messa C, Hoh CK, Phelps ME. Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 1992; 3: 339-344.